Concurrent treatment with OX40- and PD1-targeted cancer immunotherapies may be detrimental

Concurrent administration of the T-cell stimulating anti-OX40 antibody and the immune checkpoint inhibitor anti-PD1 antibody attenuated the effect of anti-OX40 and resulted in poor treatment outcomes in mice.

from Top Health News – ScienceDaily http://ift.tt/2wWOKfT
from Tumblr http://ift.tt/2xGXlAu